Helsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo® oral, NEPA IV and anamorelin in Mainland China, Hong Kong SAR and Macau SAR

12 October 2021

Helsinn Group announces oral presentation of data at AACR-NCI- EORTC relating to a potent and highly selective investigational RET inhibitor

7 October 2021

Site Selection for Life Sciences Companies in Europe – 2021 edition out now

7 October 2021

Helsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQTM (infigratinib) for Patients with Cholangiocarcinoma

29 September 2021

41a Assemblea generale ordinaria di Farma Industria Ticino

13 September 2021

Comunicato Stampa premiazione Farma Industria Ticino

10 September 2021

Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica

27 July 2021

Anna Braglia Endowed Young Investigator Award in Cancer Supportive Care, supported by Helsinn, awarded to Patrick Johnson, MD

24 June 2021

Aperte le preiscrizioni al Corso SSS in Tecnica dei sistemi – indirizzo chimico farmaceutica

31 May 2021

BridgeBio Pharma’s Affiliate QED Therapeutics and Partner Helsinn Group Announce FDA Approval of TRUSELTIQTM (infigratinib) for Patients with Cholangiocarcinoma

31 May 2021